| Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 | Frank Vinluan | 09/23/20 | Europe |
| Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function” | Frank Vinluan | 09/23/20 | Seattle |
| Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations | Sue Sutter | 09/22/20 | National |
| Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/21/20 | Boston |
| Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D | Frank Vinluan | 09/17/20 | Boston |
| BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation | Dan Stanton | 09/17/20 | Boston |
| Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline | Frank Vinluan | 09/17/20 | Boston |
| Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug | Frank Vinluan | 09/16/20 | Wisconsin |
| Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series | Editors | 09/16/20 | Boston |
| Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
| Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug | Frank Vinluan | 09/15/20 | San Francisco |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout | Frank Vinluan | 09/14/20 | San Francisco |
| Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans | Frank Vinluan | 09/10/20 | Boston |
| Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test | Frank Vinluan | 09/10/20 | San Francisco |
| Generate Bio Aims to Reveal Nature’s Protein Secrets, Create New Drugs | Frank Vinluan | 09/10/20 | Boston |
| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
| Q&A: BIO CEO Michelle McMurray-Heath Outlines Diversity Goals | Mandy Jackson | 09/05/20 | National |
| AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| New Podcast and Special Report Explore How AI Is Revolutionizing Drug Discovery and Development | Editors | 09/02/20 | National |
| Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% | Frank Vinluan | 09/01/20 | New York |
